Clinical Trials Browser

Interventional × Liver Diseases × bavituximab × Clear all

NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Phase 1 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms